References
- British Menopause Society Council. Modernizing the NHS: observations and recommendations from the British Menopause Society. Menopause Int 2011; 17(2): 41–3. doi: 10.1258/mi.2011.011015.
- Daan NMP, Fauser BCJM. Menopause prediction and potential implications. Maturitas 2015; 82(3): 257–265. doi: 10.1016/j.maturitas.2015.07.019.
- Duckitt K. Managing perimenopausal menorrhagia. Maturitas 2010; 66(3): 251–256. doi: 10.1016/j.maturitas.2010.03.013.
- Birdwood GF. Understanding Osteoporosis and its Treatment. 1996. Pearl River, NY: The Parthenon Publishing Group, Inc.
- Burger HG. Androgen production in women. Fertil Steril 2002; 77 Suppl 4: S3–S5. doi: 10.1016/s0015-0282(02)02985-0.
- Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep 2004; 119 (3): 263–270. doi: 10.1016/j.phr.2004.04.005.
- Chapin J. Von Willebrand disease in the elderly: clinical perspectives. Clin Interv Aging 2018; 13: 1531–1541. doi: 10.2147/CIA.S136931.
- Biguzzi E, Siboni SM, le Cessie S, et al. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease. J Thromb Haemost 2021; 19(1): 96–106. doi: 10.1111/jth.15116.
- Rejtö J, Königsbrügge O, Grilz E, et al. Influence of blood group, von Willebrand factor levels and age on factor VIII levels in non-severe haemophilia A. J Thromb Haemost 2020; 18(5): 1081–1086. doi: 10.1111/jth.14770
- Miesbach W, Alesci S, Krekeler S, Seifried E. Age-dependent increase of FVIII:C in non-severe haemophilia A. Haemophilia 2009; 15(5): 1022–6. doi: 10.1111/j.1365-2516.2009.02051.x.
- Miesbach W, Alesci S, Krekeler S, Seifried E. Comorbidies and bleeding pattern in elderly haemophilia A patients. Haemophilia 2009; 15(4): 894–9. doi: 10.1111/j.1365-2516.2009.02030.x.
- Seaman CD, Ragni MV. The association of aging with von Willebrand factor levels and bleeding in type 1 von Willebrand disease. Clin Appl Thromb Hemost 2018; 24(3): 434–438. doi: 10.1177/1076029617724232.
- Seaman CD, Ragni MV. The effect of age on von Willebrand factor and bleeding symptoms in von Willebrand disease. Thromb Haemost 2020; 120(08): 1159–1165. doi: 10.1055/s-0040-1713636.
- Bolton-Maggs PHB, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135(5): 603–33. doi: 10.1111/j.1365-2141.2006.06343.x.
- George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75(7): 1383–1395. doi: 10.1182/blood.V75.7.1383.1383.
- Casini A, Neerman-Arbez, de Moerloose P. Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management. Blood Rev 2021; 48: 100793. doi: 10.1016/j.blre.2020.100793.
- Siboni SM, Mannucci PM, Gringeri A. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009; 7(5): 780–6. doi: 10.1111/j.1538-7836.2009.03318.x.
- Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362 (9381): 351–354. doi: 10.1016/s0140-6736(03)14021-4.
- Schutgens REG, Voskuil M, Mauser-Bunschoten EP. Management of cardiovascular disease in aging persons with haemophilia. Hamostaseologie 2017; 37(3): 196–201. doi: 10.5482/HAMO-16-09-0037.
- Dilshad H, Yousuf RI, Shoaib MH, Jamil S, Khatoon H. Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci 2016; 352(2): 487–492. doi: 10.1016/j.amjms.2016.08.007.